WHO Approves Emergency Use Of China's Sinopharm COVID Vaccine

WHO Approves Emergency Use Of China's Sinopharm COVID Vaccine

Sinopharm could now be included in the UN-backed COVAX program distributing COVID jabs to lower-income countries.

Andrew H. Sweet
  • Sinopharm could now be included in the UN-backed COVAX program distributing COVID jabs to lower-income countries.
  • In a first for a Chinese vaccine, a decision by the WHO technical advisory group opens the possibility that Sinopharm's offering could be included in the United Nations-backed COVAX program in coming weeks or months. The vaccine could be distributed through the United Nations children's agency UNICEF and WHO's Americas regional office.
  • Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines – one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
  • The Beijing-made Sinopharm shot is one the WHO advisory group considered for the emergency use listing.
  • The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India.

Read the original story here.

Comments

Sign in or become a tippinsights member to join the conversation.
Just enter your email below to get a log in link.